Clinical Trial

A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

Name: A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07294625)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.

Trial Details

NCT Number	NCT07294625
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University Collaborators: Nanjing Legend Biotech Co.
Conditions	Multiple Myeloma
Enrollment	36 participants
Start Date	2025-12-10
Primary Completion	2027-03-31 (estimated)
Study Completion	2029-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-19